201 related articles for article (PubMed ID: 37326633)
1. [Positron emission tomography in oncology].
Czerner CP; Derlin T; Bengel FM; Weiberg D
Radiologie (Heidelb); 2023 Jul; 63(7):549-560. PubMed ID: 37326633
[TBL] [Abstract][Full Text] [Related]
2. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography-adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
Sickinger MT; von Tresckow B; Kobe C; Engert A; Borchmann P; Skoetz N
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010533. PubMed ID: 25572491
[TBL] [Abstract][Full Text] [Related]
4. Positron-emission tomography imaging in urological oncology: Current aspects and developments.
Rauscher I; Eiber M; Weber WA; Gschwend JE; Horn T; Maurer T
Int J Urol; 2018 Nov; 25(11):912-921. PubMed ID: 30103285
[TBL] [Abstract][Full Text] [Related]
5. Incidental Detection of a Hodgkin Lymphoma on 18F-Choline PET/CT and Comparison With 18F-FDG in a Patient With Prostate Cancer.
Goineau A; Colombié M; Rousseau C; Sadot-Lebouvier S; Supiot S
Clin Nucl Med; 2015 Aug; 40(8):670-1. PubMed ID: 26018683
[TBL] [Abstract][Full Text] [Related]
6. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
[TBL] [Abstract][Full Text] [Related]
7. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
Specht L
Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography in imaging evaluation of staging, restaging, treatment response, and prognosis in prostate cancer.
Jadvar H
Abdom Radiol (NY); 2016 May; 41(5):889-98. PubMed ID: 27193789
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography in the management of Hodgkin lymphoma.
Connors JM
Hematology Am Soc Hematol Educ Program; 2011; 2011():317-22. PubMed ID: 22160052
[TBL] [Abstract][Full Text] [Related]
12. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
[TBL] [Abstract][Full Text] [Related]
13. Recent developments in urologic oncology: positron emission tomography molecular imaging.
Bouchelouche K; Oehr P
Curr Opin Oncol; 2008 May; 20(3):321-6. PubMed ID: 18391633
[TBL] [Abstract][Full Text] [Related]
14. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
15. Update on positron emission tomography for imaging of prostate cancer.
Kitajima K; Murphy RC; Nathan MA; Sugimura K
Int J Urol; 2014 Jan; 21(1):12-23. PubMed ID: 23991644
[TBL] [Abstract][Full Text] [Related]
16. The use of positron emission tomography with [18F] 2-fluoro-D-2-deoxyglucose (FDG-PET) in Hodgkin and non-Hodgkin's lymphoma.
Chiusolo P; Sica S; Leone G
Hematology; 2003 Dec; 8(6):403-8. PubMed ID: 14668036
[TBL] [Abstract][Full Text] [Related]
17. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
Ferraro DA; Burger IA
Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
[TBL] [Abstract][Full Text] [Related]
18. The Impact of 68Ga-PSMA PET/CT and PET/MRI on the Management of Prostate Cancer.
Hoffmann MA; Wieler HJ; Baues C; Kuntz NJ; Richardsen I; Schreckenberger M
Urology; 2019 Aug; 130():1-12. PubMed ID: 30986486
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET in children with lymphomas.
Depas G; De Barsy C; Jerusalem G; Hoyoux C; Dresse MF; Fassotte MF; Paquet N; Foidart J; Rigo P; Hustinx R
Eur J Nucl Med Mol Imaging; 2005 Jan; 32(1):31-8. PubMed ID: 15605288
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging of prostate cancer: PET radiotracers.
Jadvar H
AJR Am J Roentgenol; 2012 Aug; 199(2):278-91. PubMed ID: 22826388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
